Objective: Approximately 7.5% of patients admitted to Intensive Care Unit (ICU) of hospitals are likely diagnosed with acute lung injury (ALI) or acute respiratory distress syndrome (ALI/ARDS), and more than one-third of the affected patients die with this disease. Despite the improvement in patient care with the availability of mechanical ventilators, mortality among these patients is unabated. Even though many drugs proved effective in preclinical studies, none is efficacious clinically, and no pharmacological treatment is insight. Statins were reported to exert anti-inflammatory effects and it was suggested that these drugs may be useful in ALI/ARDS patients. However, the initial positive results with statins were not confirmed in later studies, raising doubts about their usefulness. In the present meta-analysis, we examined the efficacy of statins in ALI/ARDS patients.
Materials And Methods: Various databases were searched to identify both randomized clinical trials and cohort studies, where statin users were compared to non-statin users. To increase the strength of the analysis, cohort studies and random clinical trials were combined in the present analysis. RevMan software from the Cochrane Collaboration was used to a conduct meta-analysis.
Results: Baseline characteristics indicated that APACHE-III score to be lower in statin users, suggesting some beneficial effects. However, mortality and severe sepsis were unchanged following statin treatment. But results also showed reduced SOFA score and increased number of ventilator-free days among statin users, indicating that statins are likely to have some beneficial effects.
Conclusions: Statin treatment of ALI/ARDS patients seems to improve health in terms of organ failure and also by lowering the need for ventilation. However, the sample size is too small to accurately assess the effects on mortality and sepsis and further investigations are needed.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.26355/eurrev_201805_15080 | DOI Listing |
Cancer Med
January 2025
Department of Urology, Cantonal Hospital Aarau, Aarau, Switzerland.
Objective: While statins have demonstrated a variety of antineoplastic effects in preclinical studies, several retrospective clinical studies and observational studies have not shown a consistent chemopreventive benefit against prostate cancer (PCa). Therefore, in this population-based cohort study, we examined the association of statin intake on prostate specific antigen (PSA) values and risk of development of PCa.
Method: N = 4,314 men from the Swiss section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) were evaluated.
Sci Rep
December 2024
School of Pharmacy, Sungkyunkwan University, 2066 Seobu-ro, Jangan-gu, Suwon, 16419, Gyeonggi-do, South Korea.
This population-based cohort study aimed to evaluate the risk of osteoporosis and fractures associated with higher-potency statin use compared to lower-potency statin use in patients with stroke, using data from the Health Insurance and Review Assessment database of South Korea (2010-2019). Patients who received statin within 30 days after hospitalization for a new-onset stroke (n = 276,911) were divided into higher-potency (n = 212,215, 76.6%) or lower-potency (n = 64,696, 23.
View Article and Find Full Text PDFWorld J Exp Med
December 2024
Department of Gastroenterology and Hepatology, University of Missouri, Columbia, MO 65212, United States.
Background: Metabolic dysfunction-associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease with a significant risk of developing hepatocellular carcinoma (HCC). Recent clinical evidence indicates the potential benefits of statins in cancer chemoprevention and therapeutics. However, it is still unclear if these drugs can lower the specific risk of HCC among patients with MASLD.
View Article and Find Full Text PDFMedicine (Baltimore)
December 2024
National Clinical Research Center for Chinese Medicine Cardiology, Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Dyslipidemia has been established as a potential risk factor for venous thromboembolism (VTE) in several observational studies. Statins and novel lipid-modifying agents are being explored for their potential in VTE prevention, encompassing deep vein thrombosis (DVT), and pulmonary embolism (PE). Nonetheless, conclusive evidence supporting the effectiveness remains uncertain.
View Article and Find Full Text PDFNutr Metab Cardiovasc Dis
November 2024
College of Pharmacy, Kyung Hee University, Seoul, Republic of Korea; Department of Regulatory Science, Graduate School, Kyung Hee University, Seoul, Republic of Korea; Institute of Regulatory Innovation Through Science, Kyung Hee University, Seoul, Republic of Korea. Electronic address:
Background And Aims: In contrast to the substantial body of clinical trial evidence, the real-world evidence regarding the efficacy of statins in the prevention of cardiovascular events among patients with type 2 diabetes mellitus (T2DM) is relatively limited. Therefore, we assessed the effectiveness of atorvastatin for the primary prevention of CV events in patients with T2DM, using a population-based data in South Korea.
Methods And Results: This retrospective cohort study was conducted using the National Health Insurance Service Customized Database (2008-2018) in South Korea.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!